Program
Levomilnacipran
Also written as “Levomilnacipran ER”, “F2695” and “Levomilnacipran Hydrochloride Extended-Release Capsules”.
Its studies are mostly in Depressive Disorder, Major · Depression · Ischemic Stroke, led by 3 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| AbbVie | 100 open or running | phase 4since Nov 7, 2014 | Aug 31, 2009 | none ahead |
| Pierre Fabre | 20 open or running | phase 3since Jul 10, 2012 | Jul 10, 2012 | none ahead |
| Zhejiang Huahai Pharmaceutical | 10 open or running | phase 3since Nov 18, 2025 | Nov 18, 2025 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Aug 31, 2009First studies: 2 phase 3 studies in Depressive Disorder, MajorNew to AbbVieAbbVie · NCT00969709, NCT00969150
- Dec 16, 20092 phase 3 studies in Depressive Disorder, MajorAbbVie · NCT01034462, NCT01034267
- Mar 10, 2010Phase 3 study in DepressionAbbVie · NCT01085812 · 734 enrolled · United States, Canada
- Dec 3, 2010Phase 2 study in Depressive Disorder, MajorAbbVie · NCT01254305 · 262 enrolled · United States
- Jun 10, 2011Phase 3 study in Depressive Disorder, MajorAbbVie · NCT01377194 · 568 enrolled · United States, Canada
- Jul 10, 2012Pierre Fabre's first study: phase 3 study in Ischemic StrokeNew to Pierre FabrePierre Fabre · NCT01639014 · 532 enrolled · Belgium, Czech Republic, France and more
- Sep 19, 2014Phase 1 study in SubjectPierre Fabre · NCT02266966 · 17 enrolled · France
- Nov 7, 2014Phase 4 study in Depressive Disorder, MajorAbbVie · NCT02288325 · 644 enrolled · United States
- Apr 28, 2015Phase 3 study in Depressive Disorder, MajorAbbVie · NCT02431806 · 552 enrolled · United States, Puerto Rico
- Jun 15, 2018Phase 3 study in Depressive Disorder, MajorAbbVie · NCT03569475 · 501 enrolled · United States
- Nov 18, 2025Zhejiang Huahai Pharmaceutical's first study: phase 3 study in Depressive Disorder, MajorNew to Zhejiang Huahai PharmaceuticalZhejiang Huahai Pharmaceutical · NCT07253207 · 392 enrolled · China
TargetBeta
“Serotonin transporter inhibitor; Norepinephrine transporter inhibitor”ChEMBL 37, by rule
Studies
All 13 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07253207Depressive Disorder, Major · China | 3 | Completed | Zhejiang Huahai Pharmaceutical | Jun 13, 2025 | 392 |
| NCT03569475Depressive Disorder, Major · United States | 3 | Completed | AbbVie | Mar 1, 2021 | 501 |
| NCT02431806Depressive Disorder, Major · United States, Puerto Rico | 3 | Completed | AbbVie | Aug 19, 2019 | 552 |
| NCT02288325Depressive Disorder, Major · United States | 4 | Completed | AbbVie | Sep 16, 2016 | 644 |
| NCT02266966Subject · France | 1 | Completed | Pierre Fabre | Sep 2014 | 17 |
| NCT01639014Ischemic Stroke · Belgium, Czech Republic, France and more | 3 | Completed | Pierre Fabre | Feb 2015 | 532 |
| NCT01377194Depressive Disorder, Major · United States, Canada | 3 | Completed | AbbVie | Mar 2012 | 568 |
| NCT01254305Depressive Disorder, Major · United States | 2 | Completed | AbbVie | Jul 2012 | 262 |
| NCT01085812Depression · United States, Canada | 3 | Completed | AbbVie | Oct 2011 | 734 |
| NCT01034462Depressive Disorder, Major · United States | 3 | Completed | AbbVie | Dec 2011 | 442 |
| NCT01034267Depressive Disorder, Major · United States | 3 | Completed | AbbVie | Jun 2012 | 828 |
| NCT00969709Depressive Disorder, Major · United States | 3 | Completed | AbbVie | May 2011 | 724 |
| NCT00969150Depressive Disorder, Major · United States | 3 | Completed | AbbVie | Nov 2010 | 362 |
How it is read
Names in the registry
- “Levomilnacipran ER”, 11 entries
- “F2695”, 2 entries
- “Levomilnacipran Hydrochloride Extended-Release Capsules”, 1 entry
- “Levomilnacipran”, 1 entry
- “F2695 SR”, 1 entry
Conditions, from the studies’ own filings
- Depressive Disorder, Major, 10 studies
- Depression, 1 study
- Ischemic Stroke, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.